Houston-based alive5 has over 800 customers using their chatbox services — and has found a special niche in sports team's websites. Photo via alive5.com

It seems like every other webpage nowadays has a virtual assistant that pops up via a chat box. A Houston startups is hoping to ride the wave of this digital marketing initiative.

Houston-based alive5 has created a platform that allows small-to-medium-sized businesses to engage customers using Chatbot Technology, from their websites, apps, SMS text-message, and social media pages.

"What we do at alive5 is really simple," says Glenn Gutierrez, COO and co-founder of alive5. "We help your business make more conversations."

Gutierrez and his co-founder Dustin Yu started out in 2017 as Alive Chat System and they were one of the first chat systems in Texas.

"Our chat system was kind of a common system that you might see on a website that says, 'Hey, how can I help you today?" says Gutierrez. "And when you press that button, somebody on the other end sends a message and says, 'Hey, how are you doing today? How can I help you?"

After exploring how to take the company, which was initially a lifestyle product, to scale, they added new products and found new ways for their clients to have more conversations with their customers.

"We had to create as many channels as possible outside of web chat," says Gutierrez. "We talked about the live chat system, moving into SMS text message, moving into social media and interestingly enough, we started moving into business cards with QR codes where people can actually scan a QR code or text a phone number and we can automatically build a relationship with a customer at an event, in person or from a billboard.

"And that activates pretty much all the rest of the system for businesses to be able to engage a customer. So we think about ourselves as the best way to help you create more conversations, not just on your website, but pretty much anywhere you would engage a customer."

The platform enjoyed a meteoric rise in the chat space due to its participation in Capital Factory's accelerator program. From there, they were placed in another accelerator program in Philadelphia, the Comcast NBCUniversal LIFT Labs Accelerator, powered by Techstars.

"Because of the boost from the accelerator programs, we developed relationships with a lot of great organizations," says Gutierrez. "Today, we service over 800 customers, including 200 of the top college sports teams and pro teams like the NBA, NFL and NHL."

The platform's collaboration helps teams sell more tickets, especially premium seat tickets, by facilitating conversations with VIP clients and allowing fans the opportunity to go to the team's website to use the automated chat solution.

"A good example of one of those is the Jacksonville Jaguars website," says Gutierrez. "You can go there and see one of our chat boxes available to assist with inquiries or questions that you may have before, during or after a game. And our solution is built for organizations with a high volume of customer interactions to automate some of those tier one questions."

Alive5 also services customers like Royal Caribbean Cruise Line, major hotel brands and other companies in the hospitality space. They are also now collaborating with Spectra Venue Management, which manages hundreds of venues throughout North America, to pilot alive5's messaging and concierge services.

Outside of their inroads in the chat space, the platform is creating AI-powered strategies to help companies maximize their communication opportunities at personal touchpoint events such as conferences and trade shows.

"With our A.I. powered business cards, we're able to take an engagement that happens at a conference, an event or at a networking session and turn that into a prospect that's now part of a company's digital lead funnel," says Gutierrez. "What we're proposing is to give them a laser-etched metal business card with the QR code. That is better than just giving them a paper business card that they will take and may or may not call you and that's it, that's the end of the interaction.

"With the QR code, a potential contact can scan it and it will send them a demo of our product to their phone and it will give them all of a client's contact details so they can reach out to that client anytime they're ready to buy. The best part about that is that now you have something that no other system can do and you have that customer's phone number available to you at any point in time."

Moving forward, the Houston-based platform wants to do everything within its power to be one of the most successful chat companies nationwide.

"I like to think about our product like a Lego set," says Gutierrez. "It's up to you to choose what package you want. I've been in the startup space for a long time and to finally see that ecosystem starting to mature to the point that businesses are more open to digitally transforming their organizations, where they're understanding the need to take risks, to try new things, that's great for us.

"When you think about a company that can help you with your communication, I want alive5 to be the first company on their minds."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.